Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need

Sayan Poursadrolah¹, Ruba Alchaikh Hassan², Ion Codreanu^{3

4}, Constantin A Dasanu^{5

6}

Affiliations

¹ Department of Medicine, Flushing Hospital Medical Center, Flushing, NY, USA.
² Department of Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
³ Translational Imaging Center, Houston Methodist Research Institute, Houston, TX, USA.
⁴ Department of Radiology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
⁵ Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
⁶ Department of Medical Oncology and Hematology, UC San Diego Health System, San Diego, CA, USA.

Editorial

Sayan Poursadrolah et al. Expert Opin Pharmacother. 2025 Jun.

. 2025 Jun;26(8):923-925.

doi: 10.1080/14656566.2025.2503850. Epub 2025 May 14.

Sayan Poursadrolah¹, Ruba Alchaikh Hassan², Ion Codreanu^{3

4}, Constantin A Dasanu^{5

6}

¹ Department of Medicine, Flushing Hospital Medical Center, Flushing, NY, USA.
² Department of Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
³ Translational Imaging Center, Houston Methodist Research Institute, Houston, TX, USA.
⁴ Department of Radiology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
⁵ Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
⁶ Department of Medical Oncology and Hematology, UC San Diego Health System, San Diego, CA, USA.

No abstract available

Keywords: Cutaneous T-cell lymphoma; bexarotene; brentuximab vedotin; denileukin diftitox-cxdl; histone deacetylase inhibitors; mogamulizumab.

Publication types